First Quarter 2018 Investor Presentation

Investor Presentation First three months of 2018 Slide 23 Sales growth driven by the diabetes pandemic Novo Nordisk reported quarterly sales Reported sales split by product segments for first three months of 2018 by therapy Diabetes and obesity Haemophilia² Long-acting insulin NorditropinⓇ Other Human insulin Growth disorders Reported sales CAGR¹: 9.8% DKK billion 35 30 25 -2.9% 20 5.4% 15 5.7% 10 11.2% Premix insulin GLP-1 Fast-acting insulin Other diabetes and obesity Haemophilia Other biopharmaceuticals 5% 9% 1% 18% 7% 10% 10 5 0 Q1 2008 1 CAGR for 10-year period 2 Haemophilia comprises NovoSeven®, NovoThirteenⓇ, NovoEight® and Refixia® changing diabetes Q1 2018 22% 18% 9% Sales of DKK 26.9 billion (5%) novo nordisk

View entire presentation